SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes

In a nationwide Danish target-trial-emulation study, starting an SGLT2 inhibitor instead of a GLP-1 receptor agonist was linked to a lower 5-year risk of chronic kidney disease and fewer acute kidney injury events in people with type 2 diabetes.